Dashboard
Manage Tickers

BGNEBeiGene, Ltd.

Nasdaq beigene.com


$ 197.25 $ -0.23 (-0.12 %)    

Wednesday, 18-Sep-2024 15:59:47 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 472.49 $ -2.05 (-0.43 %)
DIA $ 416.26 $ -1.07 (-0.26 %)
SPY $ 562.20 $ -1.67 (-0.3 %)
TLT $ 99.62 $ -1.25 (-1.24 %)
GLD $ 235.53 $ -1.83 (-0.77 %)
$ 197.28
$ 197.78
$ 199.09 x 220
-- x --
$ 197.01 - $ 199.96
$ 126.97 - $ 215.00
187,253
na
20.93B
$ 0.94
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 02-26-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-02-2023 06-30-2023 10-Q
6 05-04-2023 03-31-2023 10-Q
7 02-27-2023 12-31-2022 10-K
8 11-09-2022 09-30-2022 10-Q
9 08-08-2022 06-30-2022 10-Q
10 05-09-2022 03-31-2022 10-Q
11 02-28-2022 12-31-2021 10-K
12 11-04-2021 09-30-2021 10-Q
13 08-05-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 02-25-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
17 08-06-2020 06-30-2020 10-Q
18 05-11-2020 03-31-2020 10-Q
19 03-02-2020 12-31-2019 10-K
20 11-12-2019 09-30-2019 10-Q
21 08-08-2019 06-30-2019 10-Q
22 05-09-2019 03-31-2019 10-Q
23 02-28-2019 12-31-2018 10-K
24 11-08-2018 09-30-2018 10-Q
25 08-09-2018 06-30-2018 10-Q
26 05-09-2018 03-31-2018 10-Q
27 02-28-2018 12-31-2017 10-K
28 11-13-2017 09-30-2017 10-Q
29 08-09-2017 06-30-2017 10-Q
30 05-10-2017 03-31-2017 10-Q
31 03-22-2017 12-31-2016 10-K
32 11-10-2016 09-30-2016 10-Q
33 08-10-2016 06-30-2016 10-Q
34 05-12-2016 03-31-2016 10-Q
35 03-30-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

chinese-biotech-beigene-labeled-unique-investment-as-analyst-confident-in-lead-cancer-drug
Chinese Biotech BeiGene Labeled 'Unique In...
09/18/2024 19:20:48

JMP Securities has initiated coverage on BeiGene highlighting the Chinese biotech company as a 'unique investment opportuni...

what-analysts-are-saying-about-beigene-stock
What Analysts Are Saying About BeiGene Stock
09/18/2024 13:00:36

jmp-securities-initiates-coverage-on-beigene-with-market-outperform-rating-announces-price-target-of-288
JMP Securities Initiates Coverage On BeiGe...
09/18/2024 09:42:29

JMP Securities analyst Reni Benjamin initiates coverage on BeiGene (NASDAQ:BGNE) with a Market Outperform rating and announc...

beigene-says-israeli-ministry-of-health-approved-tevimbra-tislelizumab-as-monotherapy-for-treatment-of-adult-patients-with-unresectable-or-metastatic-oescc-after-prior-systemic-chemotherapy
BeiGene Says Israeli Ministry Of Health Ap...
09/17/2024 11:46:51

oxford-industries-reports-weak-results-joins-viper-energy-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session
Oxford Industries Reports Weak Results, Jo...
09/12/2024 12:02:18

why-champions-oncology-shares-are-trading-higher-by-over-13-here-are-20-stocks-moving-premarket
Why Champions Oncology Shares Are Trading ...
09/12/2024 09:46:55

innovent-bio-hopes-for-plus-sized-profits-from-obesity-drug
Innovent Bio hopes for plus-sized profits ...
09/06/2024 19:16:41

Key Takeaways: Sales approval for the company’s anti-obesity drug mazdutide may drag out beyond this year, potentially allow...

top-2-health-care-stocks-that-may-plunge-in-august
Top 2 Health Care Stocks That May Plunge I...
08/26/2024 11:53:01

beigene-says-fda-granted-fast-track-designation-to-bgb-16673-for-adult-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma
BeiGene Says FDA Granted Fast Track Design...
08/26/2024 10:02:32

The FDA's Fast track designation is aimed to facilitate the development and expedite the review of drugs to treat serious c...

cancer-medicines-from-merck-bristol-myers-and-beigene-in-question-as-fda-committee-to-discuss-limiting-pd-1-drugs-for-stomach-cancer
Cancer Medicines From Merck, Bristol Myers...
08/23/2024 18:10:48

The FDA's Oncologic Drugs Advisory Committee will meet on September 26 to reevaluate the approvals of checkpoint inhibitors...

jp-morgan-maintains-overweight-on-beigene-raises-price-target-to-200
JP Morgan Maintains Overweight on BeiGene,...
08/20/2024 14:13:53

JP Morgan analyst Jessica Fye maintains BeiGene (NASDAQ:BGNE) with a Overweight and raises the price target from $194 to $200.

citigroup-maintains-buy-on-beigene-raises-price-target-to-288
Citigroup Maintains Buy on BeiGene, Raises...
08/08/2024 19:12:33

Citigroup analyst Yigal Nochomovitz maintains BeiGene (NASDAQ:BGNE) with a Buy and raises the price target from $269 to $288.

beigene-q2-2024-gaap-epads-115-beats-221-estimate-sales-929166m-beat-790171m-estimate
BeiGene Q2 2024 GAAP EPADS $(1.15) Beats $...
08/07/2024 10:13:20

beigene-opens-us-biologics-manufacturing-and-clinical-rd-facility-in-new-jersey-with-800m-investment
BeiGene Opens U.S. Biologics Manufacturing...
07/23/2024 11:09:09

beigene-has-appointed-aaron-rosenberg-as-chief-financial-officer-effective-july-22-succeeding-julia-wang-who-is-departing-to-pursue-external-opportunities-and-will-stay-with-the-company-through-august-to-support-the-transition
Beigene Has Appointed Aaron Rosenberg As C...
07/18/2024 10:40:19

b-of-a-securities-maintains-neutral-on-beigene-lowers-price-target-to-1525
B of A Securities Maintains Neutral on Bei...
07/09/2024 17:20:52

B of A Securities analyst David Li maintains BeiGene (NASDAQ:BGNE) with a Neutral and lowers the price target from $180 to $...

moderna-and-walgreens-boots-alliance-were-among-the-10-biggest-large-cap-losers-last-week-june-23---june-29-are-these-in-your-portfolio
Moderna And Walgreens Boots Alliance Were ...
06/30/2024 18:21:19

10 worst performing large-cap stocks last week: Walgreens, Floor & Decor, Moderna, Birkenstock, BeiGene, Pool Corp, JD.com,...

whats-going-on-with-small-cap-cancer-focused-nurix-therapeutics-on-monday
What's Going On With Small-Cap Cancer Focu...
06/17/2024 15:47:08

Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-59...

beigene-says-it-will-present-new-data-from-sequoia-study-evaluating-brukinsa-plus-venetoclax-in-high-risk-first-line-cllsll-at-eha2024-preliminary-data-suggests-efficacy-and-tolerability
BeiGene Says It Will Present New Data From...
06/14/2024 10:04:40

BeiGene, Ltd. a global oncology company, announced the presentation of new data from the SEQUOIA study of BRUKINSA® (zanubrutin...

Core News & Articles
BriaCell Therapeutics Announces Clinical S...
05/28/2024 12:28:39

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION